Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action

J Paeshuyse, K Dallmeier, J Neyts - Current opinion in virology, 2011 - Elsevier
Roughly 20 years after the discovery of the hepatitis C virus (HCV), and 10 years after the
launch of the current standard of care (SOC) therapy, ie the combination of pegylated …
被引用次数：154 相关文章

[引用][C] Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action

J Paeshuyse, K Dallmeier, J Neyts - Current Opinion in Virology, 2011 - cir.nii.ac.jp
Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed
mechanisms of action | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action.

J Paeshuyse, K Dallmeier, J Neyts - Current Opinion in Virology, 2011 - europepmc.org
Roughly 20 years after the discovery of the hepatitis C virus (HCV), and 10 years after the
launch of the current standard of care (SOC) therapy, ie the combination of pegylated …

Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action

J Paeshuyse, K Dallmeier… - Current opinion in …, 2011 - pubmed.ncbi.nlm.nih.gov
Roughly 20 years after the discovery of the hepatitis C virus (HCV), and 10 years after the
launch of the current standard of care (SOC) therapy, ie the combination of pegylated …

Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action

J Paeshuyse, K Dallmeier, J Neyts - Current Opinion in Virology, 2011 - infona.pl
Roughly 20 years after the discovery of the hepatitis C virus (HCV), and 10 years after the
launch of the current standard of care (SOC) therapy, ie the combination of pegylated …